Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Inclusion Criteria:

• Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
• Established allergy confirmed by positive skin prick test at screening
• Willing and able to perform lung function tests and other study-related procedures
• Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later

Exclusion Criteria:

• Concomitant diagnosis of a clinically important pulmonary disease other than asthma
• Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
• History or current medical condition contraindicating methacholine challenge

Note: Additional inclusion/exclusion criteria may apply per protocol.